Change theme to redChange theme to blueChange theme to greenChoose your color
 

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil



RECOMBINANT LIGHT CHAINS OF BOTULINUM NEUROTOXINS AND LIGHT CHAIN FUSION PROTEINS FOR USE IN RESEARCH AND CLINICAL THERAPY

The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described.


Docket:RIID 99-29

Publication/Issued No.:8,153,397

Publication/Issue Date:2012-04-10

Categories: Therapeutic

More Detail:Visit USPTO.GOVExternal link

Lab:RIID

Inventor(s):SMITH, L.; BYRNE, M.


For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil
 

iSalute

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRMC Public Affairs Office at:
usarmy.detrick.medcom-usamrmc.list.webmaster@mail.mil or by telephone at (301)619-2736